Adaltis Inc.

Adaltis Inc.

July 18, 2007 09:00 ET

Adaltis HIV Ag/Ab Diagnostic Test is Ranked One of the Most Sensitive Tests in the World by a Leading Scientific Institution

MONTREAL, QUEBEC--(Marketwire - July 18, 2007) - Adaltis Inc. (TSX:ADS), an international in vitro diagnostic company, announced today that a product evaluation report published by one of the leading reference lab centers in the world, the Paul-Ehrlich-Institut (PEI), has ranked Adaltis' fourth generation test for HIV screening - DETECT-HIV™ (v.4) - as one of the top three most sensitive diagnostic kits commercially available. The Paul-Ehrlich-Institut is a German testing and research institution, reporting to the German Federal Ministry of Health.

DETECT-HIV™ (v.4) is an ultra-sensitive test offering a sensitivity of 100% and a specificity of greater than 99.8%, for detection of HIV antibodies directed against all types and subtypes of HIV and for the detection of antigen p24 to HIV-1 at the earliest stage of the disease. The report confirms the high quality of this latest-generation test and will expand new market opportunities for DETECT-HIV™ (v.4) internationally.

"We are very pleased to have received confirmation by the PEI, one of the most recognized reference lab centers in the world, that DETECT-HIV™ (v.4) is one of the top three diagnostics tests for HIV globally. Adaltis remains committed to its long standing mission of developing high quality products for infectious diseases, including state-of-the-art diagnostic products targeted at the growing HIV problems in emerging markets," said Mr. Pierre Larochelle, President and Chief Executive Officer of Adaltis.

The number of people living with HIV is still increasing every year and is a growing issue in emerging markets. The HIV virus is most easily transmitted to others during the initial period of acute HIV infection, when the viral load is especially high and when people are not yet aware of having been contaminated by the virus. The use of fourth-generation, ultra-sensitive tests, like the DETECT-HIV™ (v.4), allows the detection of the primary HIV infection itself, unlike earlier generations of tests which detect only the antibodies formed by the body in response, and the resulting earlier detection enables immediate precautionary measures to be taken to help prevent the risk of HIV transmission to a non-infected partner, to an unborn child, or through blood donations or direct blood contact. Earlier detection of HIV infection also ensures the implementation of early antiretroviral therapy to slow down the progression of the HIV infection, thereby improving patient care and quality of life.

For more information about DETECT-HIV™ (v.4), please visit: where a copy of the published study from PEI will be posted.

About Adaltis

Adaltis is an international in vitro diagnostic company that develops, manufactures and markets diagnostic systems. It aims to leverage its experience in Europe to become a leading provider of in vitro diagnostic products in emerging markets, with a particular focus on China.
With the assistance of its two strategic shareholders, CITIC Pacific Limited (a large Hong Kong-based conglomerate) and Picchio Pharma Inc. (a joint venture healthcare investment firm owned by FMRC Family Trust (a trust of which Dr. Francesco Bellini is a beneficiary), and Power Technology Investment Corporation, a subsidiary of Power Corporation of Canada), Adaltis has completed building its manufacturing facility in Shanghai. Now operational, the production facility manufactures high-quality products in a low-cost GMP environment, in order to service existing markets in Europe, while providing a platform to penetrate the high-growth Chinese in vitro diagnostic market.

Adaltis is headquartered in Montreal, with offices in China, Hong Kong, Italy, Germany and Mexico.

Caution Concerning Forward-Looking Statements

Certain statements made in this press release, including in particular the potential market opportunities for the DETECT-HIV™ (v.4) product, are forward-looking statements and are subject to important risks, uncertainties and assumptions. The Company cautions that, by their nature, forward-looking statements involve risk and uncertainty and the Company's actual actions or results could differ materially from those expressed or implied in such forward-looking statements. The forward-looking statements contained in this press release represent the expectations of Adaltis Inc. and its subsidiaries as at the date hereof and accordingly are subject to change after such date. However, Adaltis Inc. and its subsidiaries expressly disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

For additional information with respect to the risks and uncertainties and other factors that could cause the results or events predicted in these forward-looking statements to differ materially from actual results or events, please refer to the Annual Information Form of the Company filed with the Canadian securities commissions.

Contact Information